Alnylam Provides Pipeline Update, Completes Phase I Trial of Liver Cancer Drug

The company also reported its second-quarter financial results, posting narrowed losses amid decreased costs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.